

## SHCP APC Summary

Date: July 2023

Link to the full July SHCP APC minutes are available [HERE](#)

SHCP APC item	Summary of decision
<b>Bimatoprost 300mcg/ml eye drops preservative free (multidose container) formulary extension application</b>	<b>Approved</b> with a <b>PURPLE</b> (items requiring specialist recommendation without shared care guidelines) formulary coding, the formulary is annotated with 'multidose container is the preferred choice for newly initiated patients, and the extended shelf life of the brand Bimi® is 90 days.
<b>Adalimumab/ranibizumab formulary extension.</b> Additional brands of adalimumab biosimilars - <b>Yuflyma®</b> , <b>Idacio®</b> , <b>Hyrimoz®</b> and ranibizumab biosimilar - <b>Byooviz®</b> <b>Ximluci®</b>	<b>Approved</b> with a <b>RED</b> (Specialists only) formulary coding
<b>Clarification of supply route for fidaxomicin in the community during out of hours periods</b>	<p><b>Approved</b> – To review the supply of fidaxomicin in the community in 6 months and share the results with the APC in the instance of issues with current processes are highlighted to the ICB Medicines Optimisation team. Provider colleagues are encouraged to share any issues encountered with Kristina Fowle or Katie Perkins. The action will be considered closed if no issues are highlighted within the next 6 months</p> <p>Where prescriptions for fidaxomicin are received by a community pharmacy, stock should be ordered at the earliest opportunity, for same or next day delivery from wholesalers on weekdays and should be able to be supplied to the patient in a timely manner. Supply may be delayed during a weekend or bank holiday period.</p> <p>If a patient presents a prescription for fidaxomicin to a community pharmacy during a weekend or bank holiday period and there is a delay in the pharmacy being able to supply this then the pharmacy can inform the patient that if their symptoms worsen, they should attend A&amp;E for clinical assessment. Please note that A&amp;E will not be able to supply the item against a FP10 but will be able to clinically assess the patient and provide any necessary treatment.</p>
<b>Methenamine Hippurate 1g tablets new medicines application</b>	<b>Not approved</b> – to bring the application back to the APC along with the treatment pathway working with neighbouring ICBs and local providers.

<b>Luforbec Multi Dose Inhaler (MDI) formulary extension</b>	<b>Not approved</b> – Place in treatment pathway required further engagement across the local health economy.
<b>Fortisip Plant based 1.5kcal ready to drink formulary extension</b>	<b>Approved</b> with a <b>GREEN</b> (can be prescribed in any care setting) formulary coding, as a second line option to powdered products, for those who follow a plant-based diet.
<b>Bromfenac eye drops new medicine application</b>	<b>Approved</b> with a <b>PURPLE</b> (Specialist initiation without Shared Care Protocol) formulary coding for use for post-operative ocular inflammation following cataract extraction and off license for treatment of inflammation associated with uveitis and cystoid macular oedema.
<b>Bijuve® (Estradiol/Progesterone) 1mg/100mg soft capsules new medicine application</b>	<b>Approved</b> with a <b>GREEN</b> (can be prescribed in any care setting) formulary coding for continuous combined hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses.
<b>Alignment of (four) insulin products in response to the national GPL1 receptor agonist shortage summary report</b> Humulin I KwikPen®, Humulin M3 KwikPen®, Toujeo 300 units/mL SoloStar® Abasaglar KwikPen®)	<b>Approved</b> with a <b>GREEN</b> (can be prescribed in any care setting) formulary coding
<b>NICE Technology Appraisals</b>	
<b>NICE TA881</b> Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments	<b>Not recommended</b>
<b>NICE TA882</b> Voclosporin with mycophenolate mofetil for treating lupus nephritis	<b>Approved RED</b> formulary coding
<b>NICE TA883</b> Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma	<b>Not recommended</b>
<b>NICE TA884</b> Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping	<b>Terminated appraisal</b>
<b>NICE TA885</b> Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	<b>Approved RED</b> formulary coding
<b>NICE TA886</b> Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	<b>Approved RED</b> formulary coding

<b>NICE TA887</b> Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	Approved <b>RED</b> formulary coding
<b>NICE TA888</b> Risankizumab for previously treated moderately to severely active Crohn's disease	Approved <b>RED</b> formulary coding
<b>NICE TA889</b> Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma	Terminated appraisal
<b>NICE TA890</b> Difelikefalin for treating pruritus in people having haemodialysis	Approved <b>RED</b> formulary coding
<b>NICE TA891</b> Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia	Approved <b>RED</b> formulary coding
<b>NICE TA892</b> Mosunetuzumab for treating relapsed or refractory follicular lymphoma	Not recommended
<b>NICE TA905</b> Upadacitinib for previously treated moderately to severely active Crohn's disease	Approved <b>RED</b> formulary coding
<b>NICE TA907</b> Deucravacitinib for treating moderate to severe plaque psoriasis	Approved <b>RED</b> formulary coding
<b>NICE TA878</b> Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19	Approved <b>RED</b> formulary coding
<b>NICE TA902</b> Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	Approved <b>RED</b> formulary coding <b>05/09/2023 Post meeting note:</b> Following an amendment made by NICE which now highlights that providers are NHS hospital trusts and primary care a <b>PURPLE</b> formulary coding was approved virtually. This is in line with our previous purple coding decision for TA679 (dapagliflozin for treating chronic heart failure with reduced ejection fraction).
<b>NICE TA903</b> Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer	Approved <b>RED</b> formulary coding
<b>NICE TA904</b> Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer	Approved <b>RED</b> formulary coding
<b>NICE TA896</b> Bulevirtide for treating chronic hepatitis D	Approved <b>RED</b> formulary coding
<b>NICE TA897</b> Daratumumab with bortezomib and	Approved <b>RED</b> formulary coding

dexamethasone for previously treated multiple myeloma	
<b>NICE TA899</b> Esketamine for treating major depressive disorder in adults at imminent risk of suicide	<b>Terminated appraisal</b>
<b>NICE Guidelines</b>	
<b>CG181</b> Cardiovascular disease: risk assessment and reduction, including lipid modification (updated)	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
<b>NG232</b> Head injury: assessment and early management (New)	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
<b>NG191</b> COVID-19 rapid guideline: managing COVID-19 (updated)	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
<b>DISCONTINUATIONS</b>	
February 2023	Ikorel® (Nicorandil 10mg tablets)
March 2023	Lanoxin® PG (digoxin) 50micrograms/ml elixir
July 2023	Miochol-E 20mg powder and solvent for solution for intraocular irrigation vials